Back to the complete issue
Thursday, 2 April 2020

Rameda acquires generic anti-inflammatory molecule

Rameda Pharma has acquired a generic anti-inflammatory molecule, according to a statement (pdf). The unnamed molecule, which relieves pain associated with rheumatoid arthritis, psoriatic arthritis, osteoarthritis and other chronic ailments, would have been among Rameda’s top-10 selling products had it been in its lineup in 2019. An independent market research firm suggested the molecule generated revenues of EGP 71 mn last year based on its retail price. “With this agreement, Rameda gains access to a new, fast-growing therapeutic area that has displayed a 5-year CAGR of c.41% between 2015 and 2019,” the company said.

Background: Rameda had flagged the acquisition of new molecules as being high on its priority list for the use of proceeds from its 2019 IPO.

Enterprise is a daily publication of Enterprise Ventures LLC, an Egyptian limited liability company (commercial register 83594), and a subsidiary of Inktank Communications. Summaries are intended for guidance only and are provided on an as-is basis; kindly refer to the source article in its original language prior to undertaking any action. Neither Enterprise Ventures nor its staff assume any responsibility or liability for the accuracy of the information contained in this publication, whether in the form of summaries or analysis. © 2021 Enterprise Ventures LLC.